Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Prospective Phase II Study of Rituximab Combined, Lenalidomide, Dexamethasone Followed by Lenalidomide Maintenance in Patients With Newly Diagnosed Waldenström's Macroglobulinemia

NCT03697356 is registered in ClinicalTrials.gov with Kosin University Gospel Hospital as lead sponsor.

NCT NCT03697356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03697356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Prospective Phase II Study of Rituximab Combined, Lenalidomide, Dexamethasone Followed by Lenalidomide Maintenance in Patients With Newly Diagnosed Waldenström's Macroglobulinemia
Lead sponsor
Kosin University Gospel Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 6, 2019
Completion date
June 30, 2026
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

waldenström's macroglobulinemia